Study on the Effect and Mechanism of Aescine Sodium in the Treatment of Allergic Rhinitis
NCT06709079 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60
Last updated 2024-12-05
Summary
Allergic rhinitis is a common chronic non-infectious inflammatory disease of the upper respiratory tract, which affects patients' health, quality of life and work efficiency for a long time. Clinical manifestations are mainly nasal congestion, paroxysmal sneezing, clear watery nasal discharge and nasal itching, among which nasal congestion caused by nasal mucosal edema is the main manifestation of allergic rhinitis. Nasal mucosa has a rich network of arteriovenous anastomosis, and there are many large venous sinuses constitute a spongy structure, with a strong capacity for expansion and contraction, in the onset of allergic rhinitis, the volume of venous sinuses in the nasal mucosa can be rapidly changed, venous sinus expansion and filling can be induced by nasal mucosal congestion and nasal mucosal edema nasal congestion symptoms. Aescine sodium has been widely used in the clinical treatment of local tissue edema and the effect is remarkable, a large number of clinical results have proved that it has a significant anti-inflammatory, anti-edema, enhance the venous tension, improve blood circulation and anti-allergic effect, can be improved through the improvement of the vascular endothelial cell barrier, and enhance the epithelial cells close connection to improve the local edema and acute inflammation. The current treatment strategies for allergic rhinitis mainly include environmental control, medication, immunotherapy and health education, however, some patients are still unable to effectively control their symptoms in the long term after standardized treatment, and nasal congestion and runny nose cause great disturbance to the quality of their daily life. Therefore, it is urgent to investigate the mechanism of aescine sodium in relieving nasal mucosal edema in allergic rhinitis.
Conditions
- Allergic Rhinitis
Interventions
- DRUG
-
Aescine Sodium Tablets (Ocai®, Green Leaf Pharmaceuticals)
Preoperatively, patients with AR were given 2 tablets of Aescine Sodium Tablets (Ocai®, Green Leaf Pharmaceuticals) to be taken after meals, once in the morning and once in the evening, for a period of 20 days.
Sponsors & Collaborators
-
Cheng Lei
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2024-12-31
- Primary Completion
- 2025-12-31
- Completion
- 2026-09-30
Countries
- China
Study Locations
More Related Trials
-
Effects of Intranasal Corticosteroid and Montelukast On Nasal Allergen Challenges*
NCT01240889 ·Status: COMPLETED ·Phase: NA
-
Safety, Tolerability, and Pharmacokinetics of PA9159 Nasal Spray in Healthy Adult Subjects
NCT05170763 ·Status: COMPLETED ·Phase: PHASE1
-
Leukotriene D4 Nasal Provocation Test in Allergic Rhinitis
NCT01963741 ·Status: COMPLETED ·Phase: NA
-
Study on the Safety, Tolerability, and Pharmacokinetics of PA9159 Nasal Spray in Healthy Adult Subjects
NCT07345442 ·Status: COMPLETED ·Phase: PHASE1
-
Clinical Trial of TQC2938 Injection in Patients With Seasonal Allergic Rhinitis
NCT07052097 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy Study of PA9159 Nasal Spray for the Treatment of Seasonal Allergic Rhinitis
NCT05234580 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of On-demand and Continuous Administration of Nasal Spray in the Treatment of Allergic Rhinitis
NCT05080322 ·Status: RECRUITING ·Phase: PHASE4
-
Concomitant Intranasal Antihistamine and Corticosteroid in Stepwise Treatment Strategy for Allergic Rhinitis
NCT05708157 ·Status: UNKNOWN
-
Anti-inflammatory H1 Antihistamines Allergic Rhinitis
NCT02507635 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Arbidol in the Treatment of Allergic Rhinitis
NCT06462417 ·Status: RECRUITING ·Phase: NA
-
Impact Of Montelukast On Allergic Rhinitis And Its Inflammatory Makers
NCT05381207 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
A Clinical Study on the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of SHR-1819 Injection in Patients With Seasonal Allergic Rhinitis
NCT07091357 ·Status: RECRUITING ·Phase: PHASE2
-
Early Intervention in Allergic Patients
NCT05040828 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Qi-tonifying Chinese Herbal Products for Treatment of Allergic Rhinitis
NCT01631032 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Test a New Decongestant in Patients With Allergic Rhinitis Following a Nasal Allergen Challenge
NCT00562120 ·Status: COMPLETED ·Phase: PHASE2
-
Comparison of Montelukast and Azelastine in Treatment of Moderate to Severe Allergic Rhinitis
NCT04561687 ·Status: UNKNOWN ·Phase: NA
-
Efficacy and Safety of Mometasone Furoate Plus Azelastine HCl Combination Versus Mometasone Furoate Alone or Azelastine Alone in Patients With Perennial Allergic Rhinitis
NCT01470053 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Assess the Effects of Allergic Rhinitis and Co-administration of Mometasone or Oxymetazoline on the Pharmacokinetics, Safety, and Tolerability of Intranasal Esketamine
NCT02154334 ·Status: COMPLETED ·Phase: PHASE1
-
Microbial Study of Sublingual Immunotherapy Tablets in Patients With Allergic Rhinitis
NCT06741800 ·Status: NOT_YET_RECRUITING
-
Validation of the Rhinitis Control Scoring System (RCSS)
NCT00967967 ·Status: SUSPENDED ·Phase: NA
-
A Prospective, Randomized, Controlled Study Comparing the Efficacy of Intranasal Corticosteroids (INCS) Combined With Intranasal Antihistamines (INAH) and INCS Combined With Oral Antihistamines (OAH) in the Treatment of Moderate to Severe Allergic Rhinitis Symptoms
NCT07294326 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Washed Microbiota Transplantation for Allergic Rhinitis
NCT06372184 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergic Rhinitis
NCT06051786 ·Status: COMPLETED ·Phase: PHASE2
-
A Clinical Pharmacology Study of MT-2990 in Seasonal Allergic Rhinitis Patients
NCT03570957 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Bencycloquidium Bromide Nasal Spray in the Treatment of Moderate-severe Persistent Allergic Rhinitis
NCT05038202 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4